Microport Cardioflow Medtech Corporation · HKEX:2160
Microport Cardioflow Medtech — FY2024 Earnings Presentation
29 slides from Microport Cardioflow Medtech's earnings presentation, Sep 2, 2025
Slide 1: 2024 Annual Results Presentation
MicroPort CardioFlow Medtech Corporation 微创心通医疗科技有限公司 2024 Annual Results Presentation April 2025
Slide 2: Disclaimer
MicroPort CardioFlow Medtech Corporation Disclaimer This presentation was prepared by MicroPort CardioFlow Medtech Corporation (微创心通医疗科技有限公司) (the “ Company”) solely for use at the presentation for 2024 annual results releasing. The information contained in this presentation has not been reviewed by
Slide 3: Agenda
Agenda Business Product Pipeline Appendix Highlights Update 04-06 11-17 22-28 Total Solutions Financial Review 07-10 18-21 3
Slide 4: Business Highlights
Business Highlights 4
Slide 5: A Glance of Year 2024
A Glance of Year 2024 Healthy and Sustainable Development, Continuous Global Expansion To provide trustworthy and Significant universal access to Sustained loss reduction Expanded and state-of-the-art total enrichment of Healthy and high- attributed to solutions to treat deepening global quality gro
Slide 6: Business Highlights
Business Highlights Revenue Enrichment of Structural Heart Portfolio 362 mn ↑8%YoY （RMB） 2 new NMPA Approval: VitaFlow Liberty® Flex AnchorMan® LAAC 3 new CE Marks: VitaFlow Liberty® AnchorMan® LAAC & LAAA GPM 70.3% ↑1.1ppts Emerging Market Registrations: VitaFlow Liberty® in 18 countries/regions1 A
Slide 7: Total Solutions
Total Solutions 7
Slide 8: Synergized Market Strategy and Operation Optimization Propelled Sustainable Growth
Synergized Market Strategy and Operation Optimization Propelled Sustainable Growth China TAVI: Resilient Client Base & Optimized Efficiency Overseas TAVI：Rapid Expansion LAAC：Robust Growth 22% 20%YOY Top Centers 39% Market beating Countries Coverage Provinces Coverage3 Fast-Growing Centers growth in
Slide 9: Intensified Brand Building and Comprehensive Market Cultivation
Intensified Brand Building and Comprehensive Market Cultivation Differentiated Market Positioning Strategy to Drive Implantation Increment Seize the Golden Opportunity for LAAC Launch • To shift clients’ focus from short-term to long-term clinical results, highlighted VitaFlow® ’s positioning as the
Slide 10: Ongoing Commitment to Global Registrations and Vigorous Expansion
Ongoing Commitment to Global Registrations and Vigorous Expansion VitaFlow Liberty® 2021 China 8% Russia Argentina Europe Belarus 2022 Brazil Colombia 2023 Thailand Serbia Russia China Indonesia Turkey Iran 2024 Hong Kong SAR Korea CE Saudi Arabia Mexico Saudi Arabia Serbia India Thailand Malaysia C
Slide 11: Product Pipeline Update
Product Pipeline Update 11
Slide 12: Innovative and High-quality Total Solutions for Structural Heart Diseases
Innovative and High-quality Total Solutions for Structural Heart Diseases All-round Structural Heart Portfolio via In-House R&D and Collaboration with Global Partners 3 launched 2 launched 2 under R&D 2 under R&D 2 launched1 2 under R&D 2 under R&D 1 of which in CE registration progress TAVI Left At
Slide 13: VitaFlow Series: Positive Clinical Results Thanks to Advantageous Features
VitaFlow® Series: Positive Clinical Results Thanks to Advantageous Features VitaFlow® VitaFlow Liberty® Relatively lower all-cause mortality rate and major (disabling) stroke the world’s only commercialized motorized retrievable TAVI system Significantly reduced intraoperative valve-in-valve inciden
Slide 14: AnchorMan LAAC and LAAA: Brilliant Clinical Results
AnchorMan® LAAC and LAAA: Brilliant Clinical Results AnchorMan® Left Atrial Appendage Closure System Semi-closed structure formed by the “3D 12-month outcomes of the randomized controlled trial of the AnchorMan® LAAC folding” technology , Rounded and soft Safety distal end: Clinical success rate for
Slide 15: Self-developed TMVR Product: FIM Study Confirming Safety and Efficacy
Self-developed TMVR Product: FIM Study Confirming Safety and Efficacy TMVR pain points: anchoring difficulty, LVOTO risk, LV function impairment, long learning curve… World’s first dry-tissue TMVR system Low profile of stent design reducing with clinical application LVOTO (Left Ventricular Outflow T
Slide 16: AltaValve: Received Breakthrough and IDE Approval of FDA
AltaValveTM: Received Breakthrough and IDE Approval of FDA TMVR pain points: anchoring difficulty, LVOTO risk, LV function impairment, long learning curve… Product Features Atrial fixation minimizes the risk of LVOT Supra-annular design with minimal interaction with LV, preserving its structure Full
Slide 17: Innovation Intensified New Gen. Pipelines
Innovation Intensified New Gen. Pipelines TAVI LAAC & LAAA TTV VitaFlow ® IV AnchorMan® TTV product Transcatheter Aortic Valve Implantation System New Gen. LAAC & LAAA In-house Development Inherit the technical features of this series Improve recovery Minimized postoperative performance and reduce c
Slide 18: Financial Review
Financial Review 18
Slide 19: Rapid Revenue Growth Coupled by Increase in Gross Profit
Rapid Revenue Growth Coupled by Increase in Gross Profit Net Loss (RMB’000) Revenue (RMB’000) Gross Profit (RMB'000) & Gross Profit Margin Non-GAAP Operating Loss 69.5% 361,565 68.4% 35,007 (88,276) 336,215 (267,618) 251,209 229,931 (53,269) (203,916) (471,534) 2023 2024 2023 2024 2023 2024 Net Loss
Slide 20: Effective Cost Control to achieve healthy and sustainable growth
Effective Cost Control to achieve healthy and sustainable growth Co-ordinate internal and external resources, enhancing operational efficiency, and driving the business to achieve healthy and sustainable growth. Our operational expenses1 vs revenue ratio decreased by 53.8 percent points from 157.8%
Slide 21: Sufficient Cash Reserve for Future Development
Sufficient Cash Reserve for Future Development Cash Outflow from Operating Activities Cash and Cash Equivalents* (RMB'000) (RMB'000) 1,773,680 1,359,136 206,985 108,103 2023 2024 End of FY23 End of FY24 We maintained sufficient cash balance as of 31, Dec 2024 of RMB1.36 billion*, which can support u
Slide 22: Appendix
Appendix 22
Slide 23: Appendix 1: Overview of Product Pipeline
Appendix 1: Overview of Product Pipeline Product Pre-clinical Clinical trial Registration Launched VitaFlow® Successfully registered in Argentina and Thailand VitaFlow® System Launched Alwide® balloon catheter* Successfully registered in Argentina and Thailand Launched VitaFlow Liberty® (Retrievable
Slide 24: Appendix 2: TAVI Products - Clinical Data Comparison
Appendix 2: TAVI Products - Clinical Data Comparison Company Product 30-day 30-day 1-year 1-year 1-year 1-year major 2-year 2-year 3-year 3-year 4-year 4-year 5-year 5-year 6-year 6-year 7-year 7-year 8-year mortality major mortality major moderate vascular mortality major mortality major mortality
Slide 25: Appendix 3: Product Features - TAVI
Appendix 3: Product Features - TAVI Category Product Features Progress Improved coaxial release to reduce PVL (Perivalvular leakage) and valve migration risks VitaFlow Decreased vascular complications Liberty® Flex Received NMPA approval in The world’s only retrievable steering motorized delivery sy
Slide 26: Appendix 3: Product Features - TMVR
Appendix 3: Product Features - TMVR Category Product Features Progress Low profile of stent design reducing LVOTO (Left Ventricular Outflow Tract obstruction) risks Completed 20+ cases, achieved successful TMVR product Dry tissue for better biocompatibility and anti-calcification at least two-year p
Slide 27: Appendix 3: Product Features - TTV
Appendix 3: Product Features - TTV Category Product Features Progress Minimized postoperative complications due to oversizing by reducing radial support TTVR product Effective control of postoperative tricuspid regurgitation In R&D and design stage (In-house development) Simplified operation of the
Slide 28: Appendix 3: Product Features - Left Atrial Appendage Products
Appendix 3: Product Features - Left Atrial Appendage Products Category Product Features Progress Semi-closed structure formed by the 12 “3D folding” units and the frame: • combines the merits of an open and closed closure device AnchorMan® • solves the clinical pain point that the access sheath of t
Slide 29: Our Mission
Our Mission To provide trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases 29
MicroPort CardioFlow Medtech — FY2024 Earnings Presentation on 6ix